Endonovo Therapeutics annual free cash flow
2014
2018
2019
Endonovo Therapeutics Free Cash Flow (FCF) History (ENDV)
Endonovo Therapeutics reported −$2.5M in free cash flow for fiscal 2019, an increase of $344,202 from the previous fiscal year, with a free cash flow margin of −820.08%.
View full Endonovo Therapeutics company overviewEndonovo Therapeutics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2019 | 2019-12-31 | −$2.5M | $344,202 | — | −820.08% |
| 2018 | 2018-12-31 | −$2.9M | −$2.0M | — | −3468.29% |
| 2014 | 2014-12-31 | −$909,296 | — | — | −3758.66% |
Endonovo Therapeutics quarterly free cash flow
Q1.18
Q2.18
Q3.18
Q4.18
Q3.19
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q3 2019 | 2019-09-30 | −$1.0M | −$417,773 | — | −1882.89% |
| Q4 2018 | 2018-12-31 | −$716,095 | — | — | −1699.69% |
| Q3 2018 | 2018-09-30 | −$830,378 | — | — | −3897.39% |
| Q2 2018 | 2018-06-30 | −$741,610 | — | — | −5769.49% |
| Q1 2018 | 2018-03-31 | −$599,720 | — | — | −8601.84% |
Endonovo Therapeutics free cash flow growth trends
Endonovo Therapeutics's latest reported quarter, Q3 2019, generated −$1.0M in free cash flow, a decrease of $417,773 year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Endonovo Therapeutics filings at SEC.gov ↗